Detection of circulating tumor cells (CTCs) in clinically stable patients highlights the paradox of cellular residual disease despite radiologic remission, suggesting that microscopic tumor burden may persist even when imaging shows no active disease.
Persistent CTC presence indicates that minimal residual disease (MRD) may remain in the bloodstream, reflecting ongoing tumor cell dissemination at levels not detectable through conventional imaging techniques.
Patients with detectable circulating tumor cells over time demonstrated a significantly higher risk of disease recurrence and potential progression.
Longitudinal CTC monitoring provides valuable insights into tumor dynamics and may reveal early molecular signals of relapse before clinical symptoms appear.
Enumeration and characterization of CTCs can function as a non-invasive liquid biopsy tool for early detection of minimal residual disease in cancer patients.
Continuous CTC surveillance may allow clinicians to identify impending relapse earlier, enabling timely therapeutic intervention and improved disease management.
Integration of CTC-based MRD monitoring into oncology workflows could enhance personalized treatment strategies and long-term cancer surveillance.
Overall, circulating tumor cell enumeration represents a promising biomarker approach for early relapse prediction, disease monitoring, and precision oncology care.
Read Abstract